☰

Denis M. Daigle, Ph.D. - Publications

Affiliations: 
2003 McMaster University, Hamilton, ON, Canada 
Area:
Antibiotic resistance; chemically synthesizing antibiotics
Tree Info Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF. Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrobial Agents and Chemotherapy. e0128122. PMID 36541767 DOI: 10.1128/aac.01281-22  0.344
2021 Roach EJ, Uehara T, Daigle DM, Six DA, Khursigara CM. The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli. Microbiology Spectrum. e0091821. PMID 34494877 DOI: 10.1128/Spectrum.00918-21  0.33
2021 Trout RE, Zulli A, Mesaros E, Jackson RW, Boyd S, Liu B, Hamrick J, Daigle D, Chatwin CL, John K, McLaughlin L, Cusick SM, Weiss WJ, Pulse ME, Pevear DC, et al. Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes. Journal of Medicinal Chemistry. PMID 34191513 DOI: 10.1021/acs.jmedchem.1c00437  0.328
2021 Chatwin CL, Hamrick JC, Trout REL, Myers CL, Cusick SM, Weiss WJ, Pulse ME, Xerri L, Burns CJ, Moeck G, Daigle DM, John K, Uehara T, Pevear DC. Microbiological characterization of VNRX-5236: a broad spectrum β-lactamase inhibitor for rescue of the orally bioavailable cephalosporin ceftibuten as a carbapenem-sparing agent against strains of Enterobacterales expressing extended spectrum β-lactamases and serine carbapenemases. Antimicrobial Agents and Chemotherapy. PMID 34001510 DOI: 10.1128/AAC.00552-21  0.336
2019 Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ, Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M, Mangani S, Liu B, ... ... Daigle DM, et al. VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-β-lactamases, restores activity of cefepime in and . Antimicrobial Agents and Chemotherapy. PMID 31871094 DOI: 10.1128/Aac.01963-19  0.46
2019 Liu B, Trout REL, Chu GH, McGarry D, Jackson RW, Hamrick J, Daigle D, Cusick S, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier JD, Weiss WJ, Pevear DC, et al. Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. Journal of Medicinal Chemistry. PMID 31765155 DOI: 10.1021/Acs.Jmedchem.9B01518  0.42
2018 Daigle D, Vernacchio S, Xerri L, Pevear D. 1395. Defining the Magnitude of AUC:MIC Driver for Efficacy of the β-Lactamase Inhibitor VNRX-5133 When Combined with Cefepime Against KPC- and VIM/NDM-Producing Enterobacteriaceae and P. aeruginosa Open Forum Infectious Diseases. 5: S429-S429. DOI: 10.1093/Ofid/Ofy210.1226  0.331
2018 Daigle D, Hamrick J, Chatwin C, Kurepina N, Kreiswirth BN, Shields RK, Oliver A, Clancy CJ, Nguyen M, Pevear D, Xerri L. 1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa Open Forum Infectious Diseases. 5: S419-S420. DOI: 10.1093/Ofid/Ofy210.1201  0.42
2011 Fetar H, Gilmour C, Klinoski R, Daigle DM, Dean CR, Poole K. mexEF-oprN multidrug efflux operon of Pseudomonas aeruginosa: regulation by the MexT activator in response to nitrosative stress and chloramphenicol. Antimicrobial Agents and Chemotherapy. 55: 508-14. PMID 21078928 DOI: 10.1128/Aac.00830-10  0.311
2009 Caughlan RE, Sriram S, Daigle DM, Woods AL, Buco J, Peterson RL, Dzink-Fox J, Walker S, Dean CR. Fmt bypass in Pseudomonas aeruginosa causes induction of MexXY efflux pump expression. Antimicrobial Agents and Chemotherapy. 53: 5015-21. PMID 19786597 DOI: 10.1128/Aac.00253-09  0.399
2007 Daigle DM, Cao L, Fraud S, Wilke MS, Pacey A, Klinoski R, Strynadka NC, Dean CR, Poole K. Protein modulator of multidrug efflux gene expression in Pseudomonas aeruginosa. Journal of Bacteriology. 189: 5441-51. PMID 17545281 DOI: 10.1128/Jb.00543-07  0.367
2007 Dean CR, Narayan S, Richards J, Daigle DM, Esterow S, Leeds JA, Kamp H, Puyang X, Wiedmann B, Mueller D, Voshol H, van Oostrum J, Wall D, Koehn J, Dzink-Fox J, et al. Reduced susceptibility of Haemophilus influenzae to the peptide deformylase inhibitor LBM415 can result from target protein overexpression due to amplified chromosomal def gene copy number. Antimicrobial Agents and Chemotherapy. 51: 1004-10. PMID 17220413 DOI: 10.1128/Aac.01103-06  0.37
2006 Summerfield RL, Daigle DM, Mayer S, Mallik D, Hughes DW, Jackson SG, Sulek M, Organ MG, Brown ED, Junop MS. A 2.13 A structure of E. coli dihydrofolate reductase bound to a novel competitive inhibitor reveals a new binding surface involving the M20 loop region. Journal of Medicinal Chemistry. 49: 6977-86. PMID 17125251 DOI: 10.1021/Jm060570V  0.38
2005 Dean CR, Narayan S, Daigle DM, Dzink-Fox JL, Puyang X, Bracken KR, Dean KE, Weidmann B, Yuan Z, Jain R, Ryder NS. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrobial Agents and Chemotherapy. 49: 3129-35. PMID 16048914 DOI: 10.1128/Aac.49.8.3129-3135.2005  0.386
2005 Campbell TL, Daigle DM, Brown ED. Characterization of the Bacillus subtilis GTPase YloQ and its role in ribosome function. The Biochemical Journal. 389: 843-52. PMID 15828870 DOI: 10.1042/Bj20041873  0.407
2004 Li X, Zolli-Juran M, Cechetto JD, Daigle DM, Wright GD, Brown ED. Multicopy suppressors for novel antibacterial compounds reveal targets and drug efflux susceptibility. Chemistry & Biology. 11: 1423-30. PMID 15489169 DOI: 10.1016/J.Chembiol.2004.08.014  0.526
2004 Boehr DD, Daigle DM, Wright GD. Domain-domain interactions in the aminoglycoside antibiotic resistance enzyme AAC(6')-APH(2''). Biochemistry. 43: 9846-55. PMID 15274639 DOI: 10.1021/Bi049135Y  0.598
2004 Daigle DM, Brown ED. Studies of the interaction of Escherichia coli YjeQ with the ribosome in vitro. Journal of Bacteriology. 186: 1381-7. PMID 14973029 DOI: 10.1128/Jb.186.5.1381-1387.2004  0.379
2003 Zolli-Juran M, Cechetto JD, Hartlen R, Daigle DM, Brown ED. High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate. Bioorganic & Medicinal Chemistry Letters. 13: 2493-6. PMID 12852950 DOI: 10.1016/S0960-894X(03)00480-3  0.368
2002 Daigle DM, Rossi L, Berghuis AM, Aravind L, Koonin EV, Brown ED. YjeQ, an essential, conserved, uncharacterized protein from Escherichia coli, is an unusual GTPase with circularly permuted G-motifs and marked burst kinetics. Biochemistry. 41: 11109-17. PMID 12220175 DOI: 10.1021/Bi020355Q  0.334
1999 Daigle DM, Hughes DW, Wright GD. Prodigious substrate specificity of AAC(6')-APH(2"), an aminoglycoside antibiotic resistance determinant in enterococci and staphylococci. Chemistry & Biology. 6: 99-110. PMID 10021417 DOI: 10.1016/S1074-5521(99)80006-4  0.577
1999 Daigle DM, McKay GA, Thompson PR, Wright GD. Aminoglycoside antibiotic phosphotransferases are also serine protein kinases. Chemistry & Biology. 6: 11-8. PMID 9889150 DOI: 10.1016/S1074-5521(99)80016-7  0.603
1997 Daigle DM, McKay GA, Wright GD. Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. The Journal of Biological Chemistry. 272: 24755-8. PMID 9312069 DOI: 10.1074/Jbc.272.40.24755  0.608
Show low-probability matches.